David Scadden, M.D.

Gerald and Darlene Jordan Professor of Medicine, Harvard University
Director, Center for Regenerative Medicine, Massachusetts General Hospital

Dr. David Scadden is a scientific advisor to FogPharma and is the Gerald and Darlene Jordan professor of medicine at Harvard University.  He and Professor Douglas Melton founded and jointly direct the Harvard Stem Cell Institute that is the largest institute dedicated to bringing stem cell biology to medical care in the world. With Professor Melton, Dr. Scadden founded and chairs the Department of Stem Cell and Regenerative Biology Department at Harvard University, the first department to span faculties in Harvard’s history.  He is a hematologist/oncologist and directs the Center for Regenerative Medicine at the Massachusetts General Hospital and previously chaired the Hematologic Malignancies program in the MGH Cancer Center.  He has published over 300 scientific papers and book chapters and his laboratory has made fundamental contributions in how the stem cell niche regulates stem cell function and in normal and disease-corrupted hematopoiesis.

He is the recipient of numerous honors including membership in the National Academy of Medicine, the American Academy of Arts and Sciences and awards from the Doris Duke Charitable Trust, the Ellison Medical Foundation, the Burroughs Welcome Fund and the Leukemia and Lymphoma Society. He is the recipient of multiple honorary degrees. In 2016, he received the E. Donnall Thomas Prize from the American Society of Hematology.

Dr. Scadden has served or serves on the board of Scientific Counselors for the National Cancer Institute, the board of External Experts for the National Heart, Lung and Blood Institute, board of Directors of the International Society for Stem Cell Research and is an associate member of the Broad Institute of Harvard and MIT. He serves on multiple editorial boards and scientific advisory boards and is a scientific founder of Fate Therapeutics and Magenta Therapeutics, private biotechnology companies.